Yourgene Health PLC Presentation on 'Adapting during crisis'
April 07 2020 - 1:00AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
07 April 2020
Yourgene Health plc
("Yourgene Health" or the "Company")
Presentation on 'Adapting during crisis'
Manchester, UK - 7 April 2020: Yourgene Health (AIM: YGEN), a
leading international molecular diagnostics group, announces that
Hayden Jeffreys, Chief Operating Officer of Yourgene Health, will
be presenting at 4pm today at the virtual webinar event 'Adapting
during crisis' hosted by Bruntwood Sci-Tech.
Bruntwood Sci-Tech will be joined by its customers from across
Manchester and Innovation Birmingham who have adapted their
business due to COVID-19. Hayden Jeffreys will talk about how the
Company has modified its working practices to adapt to social
distancing, whilst maintaining key medical diagnostics supply to
the NHS and to its global networks. Additionally, the webinar will
cover how the Company has utilised Yourgene's state-of-the-art
facilities at Citylabs, part of the Bruntwood Sci-Tech space, to
support the contract manufacture of COVID-19 diagnostic tests.
The virtual event is free, but places are limited, so please
register here:
https://www.eventbrite.co.uk/e/bruntwood-scitech-adapting-during-crisis-online-tickets-101710316294
Yourgene Health plc via Walbrook PR
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Stifel Nicolaus Europe Limited (Sole Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations) Mob: 07980 541 893 / 07407 804 654
Lianne Cawthorne / Alice Woodings
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more information
visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAKLKELFEEFA
(END) Dow Jones Newswires
April 07, 2020 02:00 ET (06:00 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jan 2025 to Feb 2025
Premaitha (LSE:NIPT)
Historical Stock Chart
From Feb 2024 to Feb 2025
